Search

Your search keyword '"Ying Bei"' showing total 126 results

Search Constraints

Start Over You searched for: Author "Ying Bei" Remove constraint Author: "Ying Bei" Topic medicine.disease Remove constraint Topic: medicine.disease
126 results on '"Ying Bei"'

Search Results

1. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas

2. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

3. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report

4. Isolated urethral metastasis from appendiceal mucinous adenocarcinoma

5. Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

6. Adverse Histology, Homozygous Loss of CDKN2A/B, and Complex Genomic Alterations in Locally Advanced / Metastatic Renal Mucinous Tubular and Spindle Cell Carcinoma

7. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer

8. Comprehensive Genomic Analysis of Metastatic Non–Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets

9. PD40-05 NEOADJUVANT IMMUNOTHERAPY IN PATIENTS WITH RENAL CELL CARCINOMA UNDERGOING NEPHRECTOMY

10. Practice Patterns in Reporting Tertiary Grades at Radical Prostatectomy: Survey of a Large Group of Experienced Urologic Pathologists

11. Incidence of succinate dehydrogenase and fumarate hydratase–deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC

12. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases

13. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management

14. In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence

15. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma

16. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy

17. Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer

18. PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial

19. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm

20. Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models

21. Characterization of FH-deficient renal cell carcinoma

22. Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study

23. 9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas

24. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

25. Genetic Basis of SMARCB1 Protein Loss in 22 Sinonasal Carcinomas

26. Fumarate hydratase c.914T > C (p.Phe305Ser) is a pathogenic variant associated with hereditary leiomyomatosis and renal cell cancer syndrome

27. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer

28. PD47-01 GENOMIC DETERMINANTS OF NESTED VARIANT UROTHELIAL CARCINOMA

29. TGFβ Suppresses Type 2 Immunity to Cancer

30. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers

31. Challenges in Pathologic Staging of Renal Cell Carcinoma

32. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples

33. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes

34. Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect

35. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial

36. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

37. Leiomyoma With Bizarre Nuclei: A Morphological, Immunohistochemical and Molecular Analysis of 31 Cases

38. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

39. TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations

40. Primary Renal Well-differentiated Neuroendocrine Tumor Extending Into the Inferior Vena Cava

41. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course

42. TGF-β suppresses type 2 immunity to cancer

43. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights

44. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma

45. Author response: Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma

46. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma

47. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes

48. Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer - Data from a Randomized Phase III Trial

49. VSTM2A Over-expression is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney

50. A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma

Catalog

Books, media, physical & digital resources